Polypharmacy and Unplanned Hospitalizations in Patients with Rheumatoid Arthritis

Objective. Polypharmacy (PP), the prescribing of multiple drugs for an individual, is rising in prevalence. PP associates with an increased risk of adverse drug reactions (ADR) and hospital admissions. We investigated the relationship between PP, characteristics of rheumatoid arthritis (RA), and the risk of unplanned hospital admissions. Methods. Patients from a hospital RA cohort were retrospectively analyzed. Information was collected from electronic medical records. Cox proportional hazards were used to compare hospitalization risk according to levels of PP. Admissions were adjudicated to determine whether an ADR was implicated. Results. The study included 1101 patients; the mean number of all medications was 5. PP correlated with increasing age, disease duration, disease activity, and disability. At least 1 unplanned admission occurred for 16% of patients. Patients taking ≥ 10 medications had an adjusted HR for hospitalization of 3.1 (95% CI 2.1–4.5), compared to those taking 0–5 medications. Corticosteroid use associated with a doubling in adjusted risk of admission of 1.7 (95% CI 1.2–2.4). The most common reason for hospitalization was infection (28%). While in half of all admissions an ADR was a possible contributing factor, only 2% of admissions were found to directly result from an ADR. Conclusion. PP is common in RA and is a prognostic marker associated with increased risk of acute hospitalizations. Our data suggest that PP may be an indicator of comorbidity burden rather than a contributing cause of a drug-related toxicity. PP should be monitored to minimize inappropriate combination of prescribed medications. PP may be a useful predictor of clinical outcomes in epidemiologic studies.

[1]  Mary Jordan Samuel American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults , 2015, Journal of the American Geriatrics Society.

[2]  Danijela Gnjidic,et al.  Reducing inappropriate polypharmacy: the process of deprescribing. , 2015, JAMA internal medicine.

[3]  Bruce Guthrie,et al.  The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010 , 2015, BMC Medicine.

[4]  Alessandra Marengoni,et al.  Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity , 2015, BMJ : British Medical Journal.

[5]  Paul Gallagher,et al.  STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 , 2014, Age and ageing.

[6]  R. Payne,et al.  Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. , 2014, British journal of clinical pharmacology.

[7]  Jonathan Kay,et al.  Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA) , 2013, Annals of the rheumatic diseases.

[8]  Carol Coupland,et al.  Predicting risk of emergency admission to hospital using primary care data: derivation and validation of QAdmissions score , 2013, BMJ Open.

[9]  E. Molden,et al.  Severity and Management of Drug–Drug Interactions in Acute Geriatric Patients , 2013, Drugs & Aging.

[10]  W. Dixon,et al.  Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population , 2012, Rheumatology.

[11]  Xiaoyun Pan,et al.  Chronic Condition Clusters and Polypharmacy among Adults , 2012, International journal of family medicine.

[12]  D. Scott,et al.  Co-morbidities in established rheumatoid arthritis. , 2011, Best practice & research. Clinical rheumatology.

[13]  Florence T. Bourgeois,et al.  Adverse drug events in the outpatient setting: an 11‐year national analysis , 2010, Pharmacoepidemiology and drug safety.

[14]  Azeem Majeed,et al.  Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009 , 2010, Journal of the Royal Society of Medicine.

[15]  M. Hochberg,et al.  Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity , 2010, Annals of the rheumatic diseases.

[16]  M. Pirmohamed,et al.  Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes , 2009, PloS one.

[17]  Mohsen Sadatsafavi,et al.  Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. , 2008, Arthritis and rheumatism.

[18]  S. Gabriel Why do people with rheumatoid arthritis still die prematurely? , 2008, Annals of the rheumatic diseases.

[19]  P. Donnan,et al.  Development and validation of a model for predicting emergency admissions over the next year (PEONY): a UK historical cohort study. , 2008, Archives of internal medicine.

[20]  G. Kitas,et al.  Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. , 2007, Musculoskeletal care.

[21]  Josip Car,et al.  Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005 , 2007, BMC clinical pharmacology.

[22]  M. Pirmohamed,et al.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.

[23]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.

[24]  J. Hallas,et al.  Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention , 1990, Journal of internal medicine.

[25]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[26]  Diane Lacaille,et al.  A systematic review identifies valid comorbidity indices derived from administrative health data. , 2015, Journal of clinical epidemiology.

[27]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[28]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .